These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. Rockenstein E; Adame A; Mante M; Moessler H; Windisch M; Masliah E J Neural Transm (Vienna); 2003 Nov; 110(11):1313-27. PubMed ID: 14628195 [TBL] [Abstract][Full Text] [Related]
23. [Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages]. Roshchina IF; Gavrilova SI; Zharikov GA; Kalyn IaB; Kolykhalov IV; Selezneva ND Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):52-5. PubMed ID: 15704485 [TBL] [Abstract][Full Text] [Related]
24. [The efficacy of combination therapy with mexidol and cerebrolysin in chronic cerebral ischemia]. Berezhnaya SV; Yakupov EZ; Zaharov YA Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(5):23-27. PubMed ID: 27240176 [TBL] [Abstract][Full Text] [Related]
25. [Cerebrolysin in the treatment of brain injuries of moderate severity]. Talypov AE; Myachin MY; Kuksova NS; Kordonsky AY Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):98-106. PubMed ID: 25591645 [TBL] [Abstract][Full Text] [Related]
26. [Asthenic disorders and cognitive dysfunction in patients with tension headache]. Chutko LS; Surushkina SIu; Rozhkova AV; Iakovenko EA; Bykova IuL; Nikishina IS Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(5):31-5. PubMed ID: 23739500 [TBL] [Abstract][Full Text] [Related]
27. Cerebrolysin: a multi-target drug for recovery after stroke. Brainin M Expert Rev Neurother; 2018 Aug; 18(8):681-687. PubMed ID: 30004268 [TBL] [Abstract][Full Text] [Related]
28. Does rivastigmine improve cognitive functions or disability in patients with Alzheimer's disease? Cantisani TA; Celani MG; Righetti E Neuroepidemiology; 2004; 23(4):209-10. PubMed ID: 15272224 [No Abstract] [Full Text] [Related]
29. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z; Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884 [TBL] [Abstract][Full Text] [Related]
30. [Neuroplasticity: main mechanisms and their clinical significance]. Damulin IV Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(4):4-8. PubMed ID: 19491802 [TBL] [Abstract][Full Text] [Related]
31. [Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment]. Gavrilova SI; Kolykhalov IV; Fedorova IaB; Selezneva ND; Kalyn IaB; Roshchina IF; Odinak MM; Emelin AIu; Kashin AV; Gustov AV; Antipenko EA; Korshunova IuA; Davydova TA; Messler G Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(1):62-9. PubMed ID: 20436440 [TBL] [Abstract][Full Text] [Related]
32. [Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023)]. Levin OS; Voznyuk IA; Illarioshkin SN; Tkacheva ON; Bogolepova AN; Vasenina EE; Gavrilova SI; Dokukina TV; Emelin AY; Lobzin VY; Mkhitaryan EA; Khatkova SE; Yakushin MA; Yanishevskiy SN Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(9):121-130. PubMed ID: 37796079 [TBL] [Abstract][Full Text] [Related]
33. [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin]. Vereshchagin NV; Suslina ZA; Timerbaeva SL; Kashina EM; Gnezditskiĭ VV; Maksimova MIu; Rebrova OIu; Smirnova IN Ter Arkh; 2001; 73(4):22-7. PubMed ID: 11494441 [TBL] [Abstract][Full Text] [Related]
34. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. El Sayed I; Zaki A; Fayed AM; Shehata GM; Abdelmonem S Neurosurg Rev; 2018 Apr; 41(2):427-438. PubMed ID: 27539610 [TBL] [Abstract][Full Text] [Related]
35. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. Panisset M; Gauthier S; Moessler H; Windisch M; J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446 [TBL] [Abstract][Full Text] [Related]
36. Targets of cytoprotection in acute ischemic stroke: present and future. Lizasoain I; Cárdenas A; Hurtado O; Romera C; Mallolas J; Lorenzo P; Castillo J; Moro MA Cerebrovasc Dis; 2006; 21 Suppl 2():1-8. PubMed ID: 16651809 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802 [TBL] [Abstract][Full Text] [Related]